Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Marcell, Baranyi"'
Autor:
Sára Eszter Surguta, Marcell Baranyi, Laura Svajda, Mihály Cserepes, Ivan Ranđelović, Enikő Tátrai, Balázs Hegedűs, József Tóvári
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Lung cancer is the leading cause of cancer-related death globally. Metastasis is the most common reason of mortality in which hypoxia is suggested to have a pivotal role. However, the effect of hypoxia on the metastatic potential and migrato
Externí odkaz:
https://doaj.org/article/cb277a475cdd4d908f18552eefd4c861
Autor:
Péter Ábrányi-Balogh, Dávid Bajusz, Zoltán Orgován, Aaron B. Keeley, László Petri, Nikolett Péczka, Tibor Viktor Szalai, Gyula Pálfy, Márton Gadanecz, Emma K. Grant, Tímea Imre, Tamás Takács, Ivan Ranđelović, Marcell Baranyi, András Marton, Gitta Schlosser, Qirat F. Ashraf, Elvin D. de Araujo, Tamás Karancsi, László Buday, József Tóvári, András Perczel, Jacob T. Bush, György M. Keserű
Publikováno v:
Communications Chemistry, Vol 7, Iss 1, Pp 1-13 (2024)
Abstract Fragment screening is a popular strategy of generating viable chemical starting points especially for challenging targets. Although fragments provide a better coverage of chemical space and they have typically higher chance of binding, their
Externí odkaz:
https://doaj.org/article/0a79f05dcd144d4ba343eaa1f806db99
Autor:
Eszter Molnár, Marcell Baranyi, Krisztina Szigeti, Luca Hegedűs, Fanni Bordás, Zsófia Gábriel, Gréta Petényi, József Tóvári, Balázs Hegedűs, József Tímár
Publikováno v:
Pathology and Oncology Research, Vol 30 (2024)
Pancreatic adenocarcinoma is one of the deadliest forms of cancer with no effective therapeutic options. A KRAS mutation can be found in up to 90% of all pancreatic tumors, making it a promising therapeutic target. The introduction of new KRAS inhibi
Externí odkaz:
https://doaj.org/article/218556c3ae364339970c587752baa280
Autor:
Eszter Molnár, Dominika Rittler, Marcell Baranyi, Michael Grusch, Walter Berger, Balázs Döme, József Tóvári, Clemens Aigner, József Tímár, Tamás Garay, Balázs Hegedűs
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-11 (2018)
Abstract Background Currently, there are no available targeted therapy options for non-V600 BRAF mutated tumors. The aim of this study was to investigate the effects of RAF and MEK concurrent inhibition on tumor growth, migration, signaling and apopt
Externí odkaz:
https://doaj.org/article/eb03ce1342774897b38a56b7e9cee8a9
Autor:
Imre Varga, Tamás Garay, Clemens Aigner, Balázs Hegedűs, Marcell Baranyi, Afrodíté Németh, Magdolna Dank, Senji Shirasawa, Luca Hegedűs, Eszter Molnár, Dominika Rittler, István Jalsovszky, József Tóvári, József Tímár
Publikováno v:
Pathology & Oncology Research. 26:1957-1969
Bisphosphonates, despite proven antitumor effect in vitro in many tumor types, are currently used only for treatment of osteoporosis and bone metastasis. Colorectal cancer is the third most commonly diagnosed type of cancer and lacks targeted therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::315c3b93b30143ecc5ebb30ff3836ec5
https://doi.org/10.1007/s12253-019-00789-9
https://doi.org/10.1007/s12253-019-00789-9
Autor:
Luca Hegedüs, Elisabeth Livingstone, Ágnes Bánkfalvi, Jan Viehof, Ágnes Enyedi, Ágnes Bilecz, Balázs Győrffy, Marcell Baranyi, Anna-Mária Tőkés, Jeovanis Gil, György Marko-Varga, Klaus G. Griewank, Lisa Zimmer, Renáta Váraljai, Antje Sucker, Anne Zaremba, Dirk Schadendorf, Clemens Aigner, Balázs Hegedüs
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 6; Pages: 3324
OA Förderung 2022 PMCA4 is a critical regulator of Ca2+ homeostasis in mammalian cells. While its biological and prognostic relevance in several cancer types has already been demonstrated, only preclinical investigations suggested a metastasis suppr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46f04f4c32a2bb75b6e29c8bbfbd6c9d
Autor:
Dominika Rittler, Eszter Molnár, Marcell Baranyi, Tamás Garay, Luca Hegedűs, Clemens Aigner, József Tóvári, József Tímár, Balázs Hegedűs
Publikováno v:
International Journal of Molecular Sciences
Volume 21
Issue 20
International Journal of Molecular Sciences, Vol 21, Iss 7649, p 7649 (2020)
Volume 21
Issue 20
International Journal of Molecular Sciences, Vol 21, Iss 7649, p 7649 (2020)
The RAS/RAF and PI3K/Akt pathways play a key regulatory role in cancer and are often hit by oncogenic mutations. Despite molecular targeting, the long-term success of monotherapy is often hampered by de novo or acquired resistance. In the case of con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::188c3efa03a1ffcd5f4fdb19c406d886
https://duepublico2.uni-due.de/servlets/MCRFileNodeServlet/duepublico_derivate_00073734/Ritter_et_al_ijms-21-07649.pdf
https://duepublico2.uni-due.de/servlets/MCRFileNodeServlet/duepublico_derivate_00073734/Ritter_et_al_ijms-21-07649.pdf
Publikováno v:
Cancer Metastasis Reviews
KRAS is one of the most commonly mutated oncogene and a negative predictive factor for a number of targeted therapies. Therefore, the development of targeting strategies against mutant KRAS is urgently needed. One potential strategy involves disrupti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfd7ba5f616faa9a09da3bc39546308e
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85086344710
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85086344710
Autor:
Szilvia Bősze, Peter Horvath, Norbert Szoboszlai, Victor G. Mihucz, Ildikó Szabó, Christina Streli, Marcell Baranyi, Anikó Gaál
Publikováno v:
Microchemical Journal. 136:227-235
Evaluation of in vitro cytotoxicity of several Cu chelating agents - 2,2′-biquinoline, 8-hydroxyquinoline (oxine), ammonium pyrrolidinedithiocarbamate (APDTC), di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone (Dp44mT), dithizone and neocuproine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2805ab67d691b7b24b2133ac8d92b164
https://doi.org/10.1016/j.microc.2016.12.007
https://doi.org/10.1016/j.microc.2016.12.007
Autor:
Kinga, Nyíri, Gergely, Koppány, Gyula, Pálfy, István, Vida, Szilárd, Tóth, Zoltán, Orgován, Ivan, Ranđelović, Marcell, Baranyi, Eszter, Molnár, Miklós György, Keserû, József, Tóvári, András, Perczel, Beáta G, Vértessy, József, Tímár
Publikováno v:
Magyar onkologia. 63(4)
The RASopathy consortium was built from research groups of the Budapest University of Technology and Economics, Eötvös Loránd University, Semmelweis University and two startups: KINETO Lab Ltd. and Fototronic Ltd. The goal was to design and test n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fa51dbea1bdfe2df15e95eec8eca222b
https://pubmed.ncbi.nlm.nih.gov/31821386
https://pubmed.ncbi.nlm.nih.gov/31821386